What is NTM?

NTM stands for nontuberculous mycobacteria. NTM is found in the environment (soil and water) and can lead to serious lung infections.1-3

Who gets NTM infections?

NTM may colonize the airways without causing clinical disease.1 It is not completely understood why some people are susceptible to NTM infections; however, these patients often are immunocompromised or have structural lung damage at the time they become infected.1,4

What happens when you get an NTM infection?

An NTM lung infection is a chronic condition that can get worse over time and lead to frequent exacerbations and lengthy hospital stays.1,3,5-7 The infection can lead to serious decline of lung function, affecting the overall quality of life for many people with this disease.1,3,8

If you or someone you know has NTM or thinks they have NTM, we encourage you to talk with a healthcare provider about diagnosis and treatment.

NTM Clinical Trial

NTM Clinical Trial Insmed is conducting the INS-212 CONVERT Study, a global randomized, Phase III, open-label study in adult patients with nontuberculous mycobacterial (NTM) lung infection caused by Mycobacterium avium complex (MAC) that is refractory to treatment.9



1 Young JD, Balagopal A, Reddy NS, Schlesinger LS. Differentiating colonization from infection can be difficult. J Respir Dis. 2007;28(1):7-18.

2 Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185(8):881-886.

3 Lee M-R, Yang C-Y, Chang K-P, et al. Factors associated with lung function decline in patients with non-tuberculous mycobacterial pulmonary disease. PLoS One. 2013;8(3):e58214.

4 Adjemian J, Prevots DB, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014;11(1):9-16.

5 Griffith DE, Aksamit T, Brown-Elliott BA, et al; ATS Mycobacterial Diseases Subcommittee. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367- 416.

6 Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features. Am J Respir Crit Care Med. 2010;182(7):977- 982.

7 Abraham K, Dufour R, McDermott KJ, Tarr A. Pulmonary nontuberculous mycobacterial infections: healthcare resource utilization and costs in Medicare patients at a US health plan. Poster presented at: Academy of Managed Care Pharmacy (AMCP) Nexus Conference; October 26-29, 2015; Orlando, Florida.

8 Mehta M, Marras TK. Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med. 2011;105(11):1718-1725.

9 Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/results/NCT02344004?term=insmed+and+NTM&rank =2. Published September 27, 2016. Accessed September 28, 2016.